A Eden Evins1, Susanne S Hoeppner2, David A Schoenfeld3, Bettina B Hoeppner2, Corinne Cather2, Gladys N Pachas2, Kristina M Cieslak2, Melissa Culhane Maravic2. 1. Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States. Electronic address: a_eden_evins@hms.harvard.edu. 2. Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States. 3. Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.
Abstract
OBJECTIVE: To compare the effect of maintenance pharmacotherapy on sustained abstinence rates between recently abstinent smokers with schizophrenia and bipolar disorder (SBD) and general population smokers without psychiatric illness. METHOD: We performed a person-level, pooled analysis of two randomized controlled trials of maintenance varenicline, conducted in adult smokers with SBD and general population smokers, controlling for severity of dependence. Smokers abstinent after 12-weeks of openvarenicline treatment were randomly assigned to ≥12-weeks maintenance varenicline or identical placebo. RESULTS: In those assigned to maintenance placebo, the abstinence rate at week-24 was lower in those with SBD than for those without psychiatric illness (29.4±1.1% vs. 61.8±0.4%, OR:0.26, 95% CI: 0.13, 0.52, p<0.001). In smokers assigned to maintenance pharmacotherapy, however, there was no effect of diagnosis on abstinence rates at week-24 (87.2±0.8% vs. 81.9±0.2%, OR: 1.68, 95% CI: 0.53, 5.32, p=0.38). Time to first lapse was shortest in those with SBD assigned to maintenance placebo (Q1=12days, 95%CI: 4, 16), longer in those without psychiatric illness assigned to maintenance placebo (Q1=17days, 95%CI: 17, 29), still longer in general-population smokers assigned to maintenance varenicline (Q1=88, 95% CI:58,91, and longest in those with SBD who received maintenance varenicline (Q1>95days, 95%CI:non-est), (Χ23df=96.99, p<0.0001; all pairwise comparisons p<0.001). CONCLUSIONS: Following a standard 12-week course of pharmacotherapy, people with schizophrenia and bipolar disorder were more likely to relapse to smoking without maintenance varenicline treatment. Maintenance pharmacotherapy could improve longer-term tobacco abstinence rates and reduce known smoking-related health disparities in those with SMI.
RCT Entities:
OBJECTIVE: To compare the effect of maintenance pharmacotherapy on sustained abstinence rates between recently abstinent smokers with schizophrenia and bipolar disorder (SBD) and general population smokers without psychiatric illness. METHOD: We performed a person-level, pooled analysis of two randomized controlled trials of maintenance varenicline, conducted in adult smokers with SBD and general population smokers, controlling for severity of dependence. Smokers abstinent after 12-weeks of open varenicline treatment were randomly assigned to ≥12-weeks maintenance varenicline or identical placebo. RESULTS: In those assigned to maintenance placebo, the abstinence rate at week-24 was lower in those with SBD than for those without psychiatric illness (29.4±1.1% vs. 61.8±0.4%, OR:0.26, 95% CI: 0.13, 0.52, p<0.001). In smokers assigned to maintenance pharmacotherapy, however, there was no effect of diagnosis on abstinence rates at week-24 (87.2±0.8% vs. 81.9±0.2%, OR: 1.68, 95% CI: 0.53, 5.32, p=0.38). Time to first lapse was shortest in those with SBD assigned to maintenance placebo (Q1=12days, 95%CI: 4, 16), longer in those without psychiatric illness assigned to maintenance placebo (Q1=17days, 95%CI: 17, 29), still longer in general-population smokers assigned to maintenance varenicline (Q1=88, 95% CI:58,91, and longest in those with SBD who received maintenance varenicline (Q1>95days, 95%CI:non-est), (Χ23df=96.99, p<0.0001; all pairwise comparisons p<0.001). CONCLUSIONS: Following a standard 12-week course of pharmacotherapy, people with schizophrenia and bipolar disorder were more likely to relapse to smoking without maintenance varenicline treatment. Maintenance pharmacotherapy could improve longer-term tobacco abstinence rates and reduce known smoking-related health disparities in those with SMI.
Authors: L Elliot Hong; Gunvant K Thaker; Robert P McMahon; Ann Summerfelt; Jill Rachbeisel; Rebecca L Fuller; Ikwunga Wonodi; Robert W Buchanan; Carol Myers; Stephen J Heishman; Jeff Yang; Adrienne Nye Journal: Arch Gen Psychiatry Date: 2011-08-01
Authors: Douglas E Jorenby; J Taylor Hays; Nancy A Rigotti; Salomon Azoulay; Eric J Watsky; Kathryn E Williams; Clare B Billing; Jason Gong; Karen R Reeves Journal: JAMA Date: 2006-07-05 Impact factor: 56.272
Authors: Jill M Williams; Robert M Anthenelli; Chad D Morris; Joan Treadow; John R Thompson; Carla Yunis; Tony P George Journal: J Clin Psychiatry Date: 2012-05 Impact factor: 4.384
Authors: Robert M Anthenelli; Chad Morris; Tanya S Ramey; Sarah J Dubrava; Kostas Tsilkos; Cristina Russ; Carla Yunis Journal: Ann Intern Med Date: 2013-09-17 Impact factor: 25.391
Authors: Ruth S Barr; Melissa A Culhane; Lindsay E Jubelt; Rana S Mufti; Michael A Dyer; Anthony P Weiss; Thilo Deckersbach; John F Kelly; Oliver Freudenreich; Donald C Goff; A Eden Evins Journal: Neuropsychopharmacology Date: 2007-04-18 Impact factor: 7.853
Authors: Robert C Smith; Revital Amiaz; Tian-Mei Si; Lawrence Maayan; Hua Jin; Sylvia Boules; Henry Sershen; Chunbo Li; Juanjuan Ren; Yanhong Liu; Mary Youseff; Abel Lajtha; Alessandro Guidotti; Mark Weiser; John M Davis Journal: PLoS One Date: 2016-01-05 Impact factor: 3.240
Authors: Jonathan Livingstone-Banks; Emma Norris; Jamie Hartmann-Boyce; Robert West; Martin Jarvis; Emma Chubb; Peter Hajek Journal: Cochrane Database Syst Rev Date: 2019-10-28